Pharmaceuticals manufacturer Strides Shasun said it received approval from the United States Food & Drug Administration (USFDA) for ibuprofen Tablets 200 mg for over the counter sales.
According to Ri data, the US market for ibuprofen Tablets USP 200 mg (OTC) is approximately USD 520 Million.
“The approval further strengthens company’s fast growing global OTC franchise. The product will be marketed by Strides Pharma Inc in the US Market under its OTC brand Nuprin,” the firm said.
Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches, or arthritis.
It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu and is a nonsteroidal antiinflammatory drug or NSAID.
Strides Shasun, headquartered in Bangalore, has four business divisions — Regulated Markets, Emerging Markets, institutional Business and Active Pharmaceutical Ingredients.
The Company has 8 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 2 facilities for the emerging markets.
The Company has three dedicated R&D facilities in India and commercial operations in 85 countries.